Companies / Egypt
BMS Bails On Risky Markets
October 2008 | Company News AlertUS-based Bristol-Myers Squibb (BMS)'s decision to reduce its exposure to two of the most challenging emerging markets suggests that it has lost its appetite for risk. BMS has sold its Egyptian mature products business to GlaxoSmithKline (GSK) for US$210mn. Meanwhile, Pakistan's Daily Times has quoted 'well-informed sources' within Pakistan's pharmaceutical industry that have seen confidential papers circulated by BMS, which state that the company is seeking a buyer for its local
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.




